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Abstract
Objective/Background: Recurrent somatic mutations in the JAK2, calreticulin (CALR), and the MPL genes are described
as drivers of BCR-ABL1-negative myeloproliferative neoplasms (MPN) that includes polycythemia vera (PV), essential
thrombocytosis (ET), primary myeloﬁbrosis (PMF), and MPN unclassiﬁed (MPN-U).
Methods: We describe the mutation proﬁle and clinical features of MPN cases diagnosed at a tertiary care center.
JAK2V617F and MPL (S505/W515) mutations were screened by allele-speciﬁc polymerase chain reaction, while CALR
exon 9 and JAK2 exon 12 mutations were screened by fragment analysis/Sanger sequencing. Among the 1,570 patients
tested for these mutations during the study period, 407 were classiﬁed as MPN with a diagnosis of PV, ET, PMF, and
MPN-U seen in 30%, 17%, 36%, and 17%, respectively, screened.
Results: Similar to previous reports from Asian countries, the incidence of PMF was the highest among the classic
MPN. JAK2V617F mutation was detected in 90% of PV, 38% of ET, 48% of PMF, and 65% of MPN-U. JAK2 exon 12
mutations were seen in 5.7% of PV and 1.4% of PMF. CALR exon 9 mutations were seen in 33% of ET, 33% of PMF, and
12% of MPN-U. MPL mutations were detected in 2.8%, 2.7%, and 2.9% of ET, PMF, and MPN-U, respectively. Fifteen %
of PMF, 26% of ET, and 22% of MPN-U were triple negative.
Conclusion: There was a signiﬁcantly higher incidence of CALR mutation in PMF and ET cases. Our study highlights
the challenges in the diagnosis of JAK2-negative PV and the need for harmonization of criteria for the same.
Keywords: CALR, India, JAK2, MPL, Myeloproliferative neoplasm, Mutations

1. Introduction

T

he classical myeloproliferative neoplasms
(MPNs), also called the BCR-ABL1-negative
MPNs, are a group of related clonal hematologic
disorders characterized by excess accumulation of
one or more myeloid cell lineages. Polycythemia
vera (PV), essential thrombocytosis (ET), and primary myeloﬁbrosis (PMF) are categorized as classic
MPN [1]. They are clinically characterized by

nonspeciﬁc symptoms such as fatigability, pruritus,
early satiety due to splenomegaly, increased risk of
infections, and thrombotic events [2]. Disease
morbidity is associated with thromboembolic and
hemorrhagic events. The complication of the disease
by transformation to myeloﬁbrosis is seen to a
greater extent with PV than ET and to secondary
AML with PMF than with PV or ET [2,3].
In the vast majority of MPN cases, a mutation in
codon 617 of JAK2, resulting in the replacement of
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the amino acid valine with phenylalanine [V617F,
JAK2 NM_004972.3:c.1849G > T (p.Val617Phe)] is
found. This gain of function mutation is present in
approximately 96% of PV, 55% of ET, and 65% of
PMF [4]. JAK2 exon 12 mutations are described in
5% of cases of PV [4] and in PMF [5]. Point mutations in codon 515 of the thrombopoietin receptor
gene (MPL) have been reported in 5e10% of cases of
JAK2-negative ET and PMF. Mutations in the calreticulin (CALR) gene have been reported in ~20e25%
of ET and PMF [6].
Dysregulated JAK2 signaling is described as the
central phenotypic driver of BCR-ABL1enegative
MPNs. Furthermore, MPNs exhibit unexpected
levels of genetic complexity, with multiple abnormalities associated with disease progression, interactions between hereditary factors and driver
mutations, and effects related to the order in which
the mutations are acquired during the disease process [1,6,7].
Although morphology and clinical laboratory
analysis continue to play an important role in
deﬁning these conditions, emphasis on molecular
testing in MPN is made by the World Health Organization (WHO) by including JAK2, MPL, and
CALR mutations as one of the diagnostic criteria in
the 2016 update on the classiﬁcation of myeloid
neoplasms [8]. Genomic analysis is being increasingly recognized to be of signiﬁcance in prognostication in addition to diagnosis.
Most of the available data [9e11] regarding the
incidence, prevalence, distribution of subtypes,
molecular patterns, and natural history come from
the developed world. There is limited data from
low- and middle-income countries where challenges remain in diagnosing these conditions. The
population pyramid is skewed to a younger age;
therapeutic interventions are inadequate and often
delayed. The spectrum and proﬁle of classical MPNs
presenting to a tertiary center in such low- and
middle-income settings are likely to be signiﬁcantly
different than is conventionally expected [9]. There
is a paucity of large data sets describing the mutation spectrum of MPN from tertiary care centers in
India. Here, we describe the pattern of mutations
and clinical features in patients with MPN at our
center.

The chi-square test and ManneWhitney U-test
were used to compare variables. For all the tests, a
two-sided p value  0.05 was considered statistically
signiﬁcant. The analysis was done using IBM SPSS
statistics version 24.0 software (SPSS, Chicago, IL,
USA).

2. Patients and methods

3. Results

2.1. Patients

During the study period, 1570 samples were
screened for MPN panel (JAK2V617F, JAK2 exon 12,
MPL, and CALR mutations) with a suspected diagnosis of MPN (Fig. 1). Of these, 407 cases fulﬁlled the
WHO 2016 criteria for MPN and were further

All patients tested in our laboratory for JAK2
V617F, JAK2 exon 12, CALR, and MPL hotspot mutations (MPN panel) between January 2016 and

March 2020 were included in this study. Clinical and
laboratory characteristics at diagnosis or referral
were documented by reviewing the patients’ electronic records. A multidisciplinary team reviewed
the available clinical, laboratory, and histopathological information to make the diagnosis, and they
were subsequently classiﬁed as MPN based on the
WHO 2016 criteria. Cases that did not meet these
criteria and those with inadequate data were
excluded from further analysis. Chronic neutrophilic leukemia, chronic eosinophilic leukemia, and
myelodysplastic
syndrome/MPN
were
also
excluded from this analysis. Stringent criteria
(British Society for Haematology [BSH] 2019) [12]
were applied to classify cases of JAK2-negative PV
(Supplementary Table S1).
2.2. Screening of JAK2, CALR, and MPL mutations
DNA was extracted from whole blood by Gentra
Puregene, blood DNA kit (Qiagen, Hilden, Germany). DNA quality and quantity of these samples
were assessed by Nanodrop 2000 spectrophotometer (Thermo Scientiﬁc, Wilmington, DE, USA).
JAK2 V617F, CALR, MPL, and JAK2 exon 12 mutations were screened in all the samples that were
referred for MPN panel analysis. JAK2 V617F mutation was screened by an allele-speciﬁc polymerase
chain reaction assay (assay sensitivity 1%), as reported previously [4]. JAK2 exon12 mutations was
screened by Sanger sequencing, while mutations in
CALR exon 9 were screened using capillary electrophoresis-based fragment length analysis as reported previously [4,13]. The type of CALR mutation
was identiﬁed by Sanger sequencing. Four common
mutations in MPL were screened using an allelespeciﬁc oligonucleotide polymerase chain reaction
assay as reported previously [14].
2.3. Statistical analysis
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Fig. 1. Representation of MPN categorization among the cases analyzed. ET ¼ essential thrombocytosis; MPN ¼ myeloproliferative neoplasm; MPNU ¼ myeloproliferative neoplasm unclassiﬁed; PMF ¼ primary myeloﬁbrosis; PV ¼ polycythemia vera.

analyzed. The demographics of the patients are listed in Supplementary Table S2. The median age of
this cohort was 50 years (range: 1e80 years) with a
male predominance (M:F ¼ 2.1:1). All MPN cases
were subcategorized further into PV (n ¼ 123), ET (n
¼ 69), PMF (n ¼ 146), and MPN unclassiﬁed (MPNU) (n ¼ 69). Laboratory features of individual subtypes are listed (Supplementary Table S2). JAK2,
MPL, and CALR mutations were mutually exclusive
of each other.
3.1. Mutation spectrum in PV
Among the 123 patients with PV, 118 were JAK2
mutation-positive (V617F in 94% [n ¼ 111] and exon
12 mutations 6% [n ¼ 7]) (Fig. 2A). Of the seven
patients with JAK2 exon 12 mutations, one was a
missense mutation and six were indels. These patients presented with absolute erythrocytosis, which
is characteristic of JAK2 exon 12 mutations. However, bone marrow morphology was similar to that
of JAK2V617F-mutated PV with no isolated
erythroid hyperplasia. Thrombotic events such as
thrombosis of the portal vein, central vein, superior
mesenteric vein, deep veins of the lower limbs and
cardiovascular events (STEMI/ischemia) were
recorded in 19.5% (24 of the 123 cases), while
splenomegaly was seen in 34% (42 of the 123) cases.
3.2. Mutation spectrum in ET
The median age at diagnosis of the patients classiﬁed as having ET (n ¼ 69) was 36 years (range:
1e78). Mutations identiﬁed in the driver genes in
this group were: JAK2V617F (37.6%), CALR (33.3%),
and the MPL (2.8%) (Fig. 2B). Among the JAK2wt/
MPLwt CALR-mutated cases, type 2 was more common (52%; n ¼ 12), followed by type 1 (44%; n ¼ 10)
and a 34 base pair deletion was classiﬁed as type 1
like (c.1092_1125del; p.E364Dfs*55) (4%) (Table 1).

No mutation in any of the driver genes was identiﬁed in 26% (n ¼ 18) cases.
Comparison of demographics in patients with ET
having different mutations (Table 2) showed a
signiﬁcantly higher platelet count and a lower total
leucocyte count in the CALR-mutated ET than the
JAK2-mutated ET. Patients who were categorized as
triple-negative ET were signiﬁcantly younger with
lower hemoglobin and higher platelet counts when
compared with patients with ET having a mutation
in any of the three driver genes.
Thrombotic events were recorded in 13% (n ¼ 9)
among the 69 cases of ET in this study. These
included occlusions in the retinal artery, the coronary artery leading to ischemia, thrombosis of major
cerebral vessels, deep vein thrombosis, and one case
of extrahepatic portal vein obstruction. Splenomegaly was seen in 17.3% (n ¼ 12).
3.3. Mutation spectrum in PMF
Among the 146 cases classiﬁed as PMF,
JAK2V617F, CALR, and the MPL mutations were
seen in 48.3%, 32.9%, and 2.7% of them, respectively
(Fig. 2C). Of the JAK2wt/MPLwt cases, six different
types of CALR mutations were identiﬁed. The majority of these were type 1, (75%; n ¼ 36), 17% (n ¼ 8)
were type 2, 6% (n ¼ 3) were type 1-like, and one
was classiﬁed as other type (2%) (Table 1). A comparison of demographics in patients with PMF
having different mutations (Table 2) showed that
patients with CALR-mutated PMF had higher
platelet counts than JAK2-mutated PMF. Patients
who had no mutation in any of the driver genes
were younger and had lower platelet counts and
LDH values when compared with PMF with mutation in any of the driver genes.
A CALR mutation was detected in one case
(c.1099_1152delinsAG; p.L367Rfs*46) which was
novel in terms of a genomic change where there was
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Fig. 2. Mutation proﬁle of polycythemia vera. (A) Essential thrombocytosis; (B) primary myeloﬁbrosis; (C) MPN-U; (D) in the present study. Note.
CALR ¼ calreticulin; MPL ¼ myeloproliferative leukaemia virus oncogene; MPN-U ¼ myeloproliferative neoplasm unclassiﬁed.

an indel (complex deletion insertion) involving an
insertion of two nucleotides AG in the alternate
allele along with a 54 base pair deletion. This molecular event, however, resulted in a protein change
similar to the type 1 deletion except the ﬁrst amino
acid change is arginine instead of threonine. Hence,
this was classiﬁed as type 1-like based on the predicted effect on three different stretches of negatively charged amino acids of the wild-type CALR
sequence (Fig. 3). Tryptophan was replaced by
leucine at codon 515 (c.1544G > T; p.W515L) in 75%
(n ¼ 3) of the MPL-mutated cases and in one case the
substituted amino acid was lysine (MPL:p.W515K).
No mutation in any of the driver genes was identiﬁed in 15% (n ¼ 22) of cases.

Thrombotic events were recorded in only ﬁve
patients with PMF. Splenomegaly ranging from tip
palpable to massive splenomegaly (2e28 cm) was
observed in 111 of 146 cases. Two cases underwent a
splenectomy at the time of diagnosis.
3.4. MPN-U
Patients with overlapping features that could not
be further categorized as any particular classical
MPN (n ¼ 69) were placed under the MPN-U entity.
JAK2V617F mutations were identiﬁed in 65% (n ¼
44), CALR mutations in 11.6% (n ¼ 8) (seven with
type 1 and one with type 2), and MPL mutation in
2.9% (n ¼ 2) (p.W515K) of these patients (Fig. 2D).

Table 1. Spectrum of Calreticulin (CALR) mutations identiﬁed in PMF, ET, and MPN-U in our study.
Mutation (CDS); amino acida

c.1099_1150del; p.L367Tfs*46
c.1154_1155insTTGTC; p.K385Nfs*47
c.1097_1130del; p.R366Kfs*53
c.1100_1145del; p.L367Qfs*48
c.1099_1152delinsAG; p.L367Rfs*46
c.1120_1125delinsTGCGT; p.K374Cfs*56
c.1092_1125del; p.E364Dfs*55

Type of mutation

Type-1; 52 bp deletion
Type-2; 5 bp insertion
Type-1 like; 34 bp deletion
Type-1 like; 46 bp deletion
Type-1 like
Other
Type-1 like; 34 bp deletion

COSMIC
mutation ID

Number of cases
PMF
(N ¼ 48)

ET
(N ¼ 23)

MPN-U
(N ¼ 8)

COSM1738055
COSM1738056
COSM1738357
COSM1738150
Novel
COSM3355758
COSM1738333

75% (N ¼ 36)
17% (N ¼ 8)
6% (N ¼ 3)

44% (N ¼ 10)
52% (N ¼ 12)
d

87.5% (N ¼ 7)
12.5% (N ¼ 1)
d

2% (N ¼ 1)
d

d
4% (N ¼ 1)

d
d

Note. ET ¼ essential thrombocytosis; MPN-U ¼ myeloproliferative neoplasm unclassiﬁed; PMF ¼ primary myeloﬁbrosis.
a
Transcript ID: CALR-201 ENST00000316448.10; RefSeq: NM_004343.4 for all the mutations in the CALR gene described in this study.

Table 2. Laboratory characteristics of essential thrombocytosis (n ¼ 69) and primary myeloﬁbrosis (n ¼ 146) patients according to mutation proﬁles in this study.

ET (mutation-positive)
ET (mutation-positive)

Triple-negative ET
(Mutated vs. triple-negative)
p value*
(JAK2V617F vs. CALR)
p value*
(CALR vs. triple-negative)
p value*
(JAK2 vs. triple-negative)
p value*
PMF (mutation-positive)
PMF (mutation-positive)
JAK2
CALR
MPL
Triple-negative PMF
(Mutated vs. triple-negative)
p value*
(JAK2V617F vs. CALR)
p value*
(CALR vs. triple- negative)
p value*
(JAK2 vs. triple-negative)
p value*

Age (yr)

M:F
(% males)

Hemoglobin
(g/dL)

Hematocrit

Total WBC
count (109/L)

Platelet count
(109/L)

LDH (U/L)a

51 (74)
26 (37.6)
23 (33.3)
2 (2.9)
18 (26)
d

42 (12e78)
46 (12e78)
37 (24e65)
(66, 62)
18 (1e60)
0.002

24:27 (47)
11:15 (42.3)
12:11 (52)
01:01
7:11 (38.8)
0.54

12.9 (8.9e16)
12.8 (10.1e15.7)
12.9 (8.9e16)
13.1
11.9 (9.5e14.3)
0.001

39.6 (27.5e47.5)
39.8 (31.3e47.5)
39.2 (27.5e46.4)
39.1 (38.7e39.6)
35.6 (29.5e43.5)
0.0002

10.2 (5.2e55)
11.3 (5.2e36.3)
9.6 (5.8e55)
6.7 (5.4e8.1)
10.2 (4.4e15.4)
0.58

875 (462e2,368)
779 (462e1,856)
1,045 (657e2,368)
716 (672e760)
1,190 (622e2,708)
0.02

622 (338e3820)
601.5 (401e3820)
629 (423e1589)
569
618 (338e1,117)
0.8

d

0.42

0.48

0.91

0.25

0.02

0.01

0.56

d

0.002

0.54

0.01

0.009

0.09

0.32

0.8

d

0.001

0.82

0.004

0.0001

0.36

0.004

0.98

124 (85)
70 þ 2b
(47.9 þ 1.4)
48 (32.8)
4 (2.7)
22 (15)
d

54 (31e80)
55 (36e80)

87:38 (69.6)
47:23 (67)

9.6 (3.7e15.8)
9.85 (3.8e15.8)

29.9 (11.6e54.2)
31.3 (11.6e54.2)

8.7 (1.8e197.4)
11.5 (1.8e152.5)

243 (7e1664)
211.5 (7e1664)

1,162 (403e3,896)
1,144 (403e3,687)

50 (31e76)
61 (51e74)
42 (14e64)
0.002

36:12 (75)
02:02
16:6 (72.7)
0.76

10.1 (3.7e14.7)
8 (7.6e9.2)
8.4 (5.9e14.7)
0.07

29.9 (11.7e44.4)
25.7 (24e28.4)
27.9 (18.3e42.5)
0.17

7.85 (2.5e197.4)
5.35 (4.2e21.7)
7 (1.3e66.5)
0.41

295.5 (9e1565)
104.5 (63e342)
87.5 (7e1371)
0.02

1,235 (562e3,896)
1,490.5 (1,157e2,700)
723.5 (241e1803)
0.001

d

0.013

0.84

0.81

0.66

0.07

0.01

0.24

d

0.026

0.83

0.95

0.94

0.42

0.68

0.002

d

<0.00001

0.62

0.09

0.17

0.16

0.1

0.006
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JAK2
CALR
MPL

N (%)

Note. CALR ¼ calreticulin; ET ¼ essential thrombocytosis; LDH ¼ lactate dehydrogenase; MPL ¼ myeloproliferative leukaemia virus oncogene; PMF ¼ primary myeloﬁbrosis; WBC ¼
white blood cell.
*
All p values were calculated using the c2 test for categorical variables and the ManneWhitney U test for continuous variables. Signiﬁcant values are in boldface. a- Only cases with
documented LDH values were included for analysis in the table [For ET: JAK2 positive (n¼16); CALR positive (n¼19); MPL positive (n¼1) and Triple negative (n¼13)]. [For PMF with
mutation (n¼105); JAK2 (n¼62); CALR (n¼39); MPL (n¼4); TN-PMF (n¼20)]. b- patients with JAK2 exon12 mutations

17

18
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Fig. 3. Alignment of C-domain in wild-type and mutant calreticulin (CALR) proteins. The reference amino acid sequence starts from codon A361:
acidic, basic, and neutral residues are in red, blue, and green, respectively. All the variants involved three different stretches of negatively charged
amino acids, here deﬁned as I, II, and III, and highlighted in red in the wild-type sequence. Type 1-like mutations predict deletion of stretches II and III
(as happens with the L367fs*46 or type 1 mutation), while type 2-like mutations predict conservation of all three stretches (as happens with the
K385fs*47 or type 2 mutation); other types involve deletion of stretches III exclusively.

No mutations in any of the driver genes were
identiﬁed in 21.7% (n ¼ 15) of these cases. Both
arterial and venous thrombotic events were recorded in 24.6% (n ¼ 17) cases. Splenomegaly was
observed in 49% (34/69) cases.

4. Discussion
The discovery of mutations in the three driver
genes (JAK2, CALR, and MPL) has signiﬁcantly
contributed to the understanding of the classical
BCR-ABL1-negative MPN. The introduction of mutations in one of the driver genes as a major WHO
criterion highlights the importance of testing for
these markers in the diagnosis, classiﬁcation, and
prognosis of various MPN subtypes. Our study is
one of the largest single-center studies on MPN
from India, where we report the proportion of MPN

patients with PV, ET, PMF, and MPN-U of 30.2%,
17%, 35.8%, and 17%, respectively. When compared
with the registry data from other Asian countries,
the frequency of PMF was higher and ET was lower
in our study group [9].
JAK2V617F mutation accounts for ~95% of PV and
mutation in exon 12 contributes to a further 2e3% of
these cases. Classiﬁcation of cases presenting with
persistent and signiﬁcant erythrocytosis which are
JAK2-negative is difﬁcult and are classiﬁed as ‘JAK2negative PV’ only after excluding all possible causes
of secondary erythrocytosis. Stringent criteria for
this entity, as laid out by the BSH 2019 guidelines,
aid in differentiating this rare entity from idiopathic
and secondary erythrocytosis. In this study,
JAK2V617F accounted for 90.3% and exon 12 mutations, 5.7% of PV.

Table 3. Comparison of frequencies of driver mutations in myeloproliferative neoplasms.

PV

ET

PMF

Kim et al. (N ¼ 58) [25]
Pardanani et al. (N ¼ 220) [26]
Passamonti et al. (N ¼ 338) [15]
Ancochea et al. (N ¼ 99) [27]
Rabade et al. (N ¼ 20) [28]
Present study (N ¼ 123)
Kim et al. (N ¼ 79) [25]
Tefferi et al. (N ¼ 299) [18]
Rotunno et al. (N ¼ 576) [29]
Rabade et al. (N ¼ 34) [28]
Present study (N ¼ 69)
Kim et al. (N ¼ 54) [25]
Tefferi et al. (N ¼ 254) [19]
Sazawal et al. (N ¼ 80) [30]
Rabade et al. (N ¼ 59) [28]
Present study (N ¼ 146)

Median age
(range), yr

JAK2
V617F (%)

JAK2 Exon
12 (%)

JAK2negative (%)

CALR
(%)

MPL
(%)

Triplenegative (%)

57.4 (25.8e75.9)
d
d
69 (20e94)
50 (31e83)
51 (21e75)
55.0 (19e84)
56 (15e91)
58.1 (13e93)
46 (21e76)
36 (1e78)
62 (8e83)
64 (32e87)
48 (32e63)
53 (16e81)
52 (14e80)

87.9
97
95
94
100
90.3
63.3
53
64.1
61.7
37.8
57.4
58
56.2
57.6
48

3.5
2
4
3
d
5.7
d
d
d
d
d
d
d
d
d
1.4

8.6
1
1
3
d
4
d
d
d
d
d
d
d
d
d
d

d
d
d
d
d
d
17.7
32
15.5
15.1
33.3
14.8
25
11.2
23.7
32.9

d
d
d
d
d
d
2.5
3
4.3
9.1
2.9
9.3
8.3
0
3.4
2.7

d
d
d
d
d
d
16.5
12
16.1
15.2
26
20.4
8.7
32.6
15.3
15

Note. CALR ¼ calreticulin; ET ¼ essential thrombocytosis; MPL ¼ myeloproliferative leukaemia virus oncogene; PMF ¼ primary
myeloﬁbrosis; PV ¼ polycythemia vera.
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Conﬁrming the diagnosis of JAK2-negative PV has
been a challenge. Although 52 cases in this study
were categorized as JAK2-negative PV based on the
WHO 2016 criteria for PV, only ﬁve of these cases
met the BSH 2019 criteria. The WHO criteria for the
diagnosis of PV are less stringent and lack a separate criterion for labeling JAK2-negative PV, while
the BSH criteria are more stringent in terms of
different hematocrit requirements and other additional criteria like splenomegaly and WBC counts.
The frequency of JAK2V617F mutation in the present
study in PV cases is less than in published studies
[15e17]. Further research focusing on the identiﬁcation of a possible genetic etiology for these JAK2negative PV cases is warranted.
In this study group, the proportion of MPN patients with ET is less when compared with registry
data from other Asian countries [9]. Comparison
with previous studies showed that the mutation
proﬁle of ET cases in our study was different. JAK2mutated ET cases were fewer, while CALR-mutated
ET and triple-negative cases were higher (Table 3).
CALR-mutated ET cases were younger, had signiﬁcantly less hemoglobin, and greater platelet counts
compared with the JAK2-mutated ET cases (Table 2).
Triple-negative ET cases presented at a younger age
with a lower hemoglobin and a higher platelet count
than JAK2-mutated ET cases. This observation is in
concordance with a previous report [18]. A lower
overall median age of the ET patients in this study
can be explained by the skewing of data due to a
larger number of triple-negative ET cases who were
younger at presentation.
The spectrum of mutations in the driver genes in
patients with PMF was different in our study. In
comparison to published data, though the frequency
of JAK2V617F-mutated cases was comparable
(~50%), detection of JAK2 exon 12 mutations adds to
the varied molecular spectrum of this group. CALRmutated cases were higher while the frequencies of
MPL-mutated PMF and triple-negative cases were
comparable. CALR-mutated PMF cases were significantly younger and had signiﬁcantly higher platelet
counts than those with JAK2-mutated PMF (Table 2).
However, there was no signiﬁcant difference in
hemoglobin and total leukocyte count as described
in previous studies [19e21]. Among the CALRmutated MPN, type 1 CALR mutation (52 bp deletion) was more common in PMF than in ET (75% vs.
44%) and type 2 CALR was more common in ET than
PMF (52% vs. 17%) in our study. This is in concordance with previously published data [21,22].
In our study, 78.2% of the patients categorized as
MPN-U carried a mutation in one of the three driver
genes, with JAK2V617F being the most frequently
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represented (65%) followed by CALR mutations
(11.2%). This is comparable to a previous study on
MPN-U [23]. A more complete molecular characterization of these cases would not only help in
identifying the driver mutations, but also in understanding whether or not these cases represent only a
prodromal or advanced phase of the classic BCRABL1-negative MPNs.
Previous
study
using
the
whole-exome
sequencing approach on cases of triple-negative ET
and PMF has identiﬁed noncanonical mutations in
JAK2 and MPL genes [24]. A possible hereditary
thrombocytosis, owing to the predominant younger
age at presentation (median age 18 years for triplenegative ET) in this group cannot be excluded.
Our study provides a large data set from India on
the mutation spectrum and demographics of MPN.
Future directions of this study are on the role of next
generation sequencing in cases with features of
MPNs where no mutation was identiﬁed in any of
the driver genes (triple negative) in establishing
clonality or excluding reactive conditions.
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